The immunotherapeutic treatment of various cancers with an increasing number of immune
checkpoint inhibitors (ICIs) has profoundly improved the clinical management of advanced …

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1
(PD-1) are inhibitory checkpoints that are commonly seen on activated T cells and have …

The use of immune checkpoint inhibitors to treat urothelial carcinoma (UC) is increasing
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …

Cancer is a disease of major concern worldwide and is the second leading cause of
mortality. 1 The United States remains one of the countries with the highest incidence rates …

Urothelial carcinoma therapy is a rapidly evolving and expanding field. Traditional cytotoxic
chemotherapy regimens have not produced optimal long-term outcomes, and many …

Background This study compared real-world outcomes of metastatic renal-cell carcinoma
(mRCC) patients treated with tyrosine kinase inhibitors or nivolumab plus ipilimumab …

Background KEYNOTE-181, ATTRACTION-3, and ESCORT trials have opened the era of
programmed death 1 (PD-1) inhibitors in the second-line therapy for esophageal squamous …

Abstract Background The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant
nivolumab over placebo after radical surgery in patients with high-risk muscle-invasive …

Methods A multidisciplinary working group drafted a management algorithm for advanced
urothelial carcinoma using “consensus development conference” methodology. A targeted …

Disclaimer In an effort to expedite the publication of articles, AJHP is posting manuscripts
online as soon as possible after acceptance. Accepted manuscripts have been peer …